Literature DB >> 28094

Preliminary data on antiserotonin effects of oxatomide, a novel anti-allergic compound.

J M Van Nueten, R Xhonneux, P A Janssen.   

Abstract

Oxatomide or R 35443, 1-(3-[4-(diphenylmethyl)-1-piperazinyl]propyl)-1,3-dihydro--2H-benzimidazol-2-one, a compound with potent antihistaminic and anti-anaphylactic activities, shows specific antiserotonin effects on isolated caudal arteries of the rat. In vivo it is a powerful antagonist of bronchospasm induced by serotonin and by histamine; it has no anticholinergic effects and does not affect blood pressure in spontaneously hypertensive rats. These antiserotonin properties of oxatomide may contribute significantly to its anti-allergic activity.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 28094

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  6 in total

1.  Suppression of PAF-induced bronchoconstriction in the guinea-pig by oxatomide: mechanism of action.

Authors:  F P Nijkamp; G Folkerts; J R Beetens; F De Clerck
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-07       Impact factor: 3.000

2.  Rocastine (AHR-11325), a rapid acting, nonsedating antihistamine.

Authors:  J C Nolan; D J Stephens; A G Proakis; C A Leonard; D N Johnson; B F Kilpatrick; M H Foxwell; J M Yanni
Journal:  Agents Actions       Date:  1989-08

3.  In vitro studies on the mechanism of action of a new antiallergic, Ro 21-7634.

Authors:  A F Welton; W C Hope; H J Crowley; R A Salvador
Journal:  Agents Actions       Date:  1981-07

4.  Pulmonary vascular actions of the antihistamine oxatomide during hypoxia.

Authors:  A Tucker
Journal:  Agents Actions       Date:  1980-06

5.  Ro 21-7634, a new antiallergic agent with potent oral activity.

Authors:  R A Salvador; L B Czyzewski; H Baruth; A Hooper; A Medford; D Miller; T van Trabert; B Yaremko; A F Welton
Journal:  Agents Actions       Date:  1981-07

Review 6.  Oxatomide. A review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  D M Richards; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-03       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.